Melanoma Shrinks With Injection After Anti-PD-1 Progression

Melanoma Shrinks With Injection After Anti-PD-1 Progression

Intratumoral injection of a toll-devour receptor (TLR) agonist showed ability for reversing PD-(L)1 resistance in melanoma, a preliminary scientific trial showed. A filled with 23.5% of patients with metastatic melanoma answered to intratumoral CMP-001 and systemic pembrolizumab (Keytruda), including seven…